References
- Antonen J, Leppänen I, Tenhunen J, et al. A severe case of puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Scand J Infect Dis. 2013;45(6):494–496.
- Laine O, Leppänen I, Koskela S, et al. Severe puumala virus infection in a patient with a lymphoproliferative disease treated with icatibant. Infect Dis. 2015;47(2):107–111.
- Tuiskunen Bäck A, Rasmuson J, Thunberg T, et al. Clinical and genomic characterisation of a fatal puumala orthohantavirus cae with low levels of neutralizing antibodies. Infect Dis. 2022;54(10):766–772.
- Malchair P, Giol J, García V, et al. Three-day icatibant on top of standard care in patients with COVID-19 pneumonia (ICAT·COVID): a randomized, open-label, phase 2, proof-of-concept trial. Clin Infect Dis. 2023;ciac984.
- Vaheri A, Strandin T, Hepojoki J, et al. Uncovering the mysteries of Hantavirus infections. Nat Rev Microbiol. 2013;11(8):539–550.
- Kanerva M, Paakkala A, Mustonen J, et al. Pulmonary involvement in nephropathia epidemica: radiological findings and their clinical correlations. Clin Nephrol. 1996;46(6):369–378.
- Vaheri A, Strandin T, Jääskeläinen AJ, et al. Pathophysiology of a severe case of puumala Hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Antiviral Res. 2014;111:23–25.
- Han XY, Hellerstedt BA, Koller CA. Postsplenectomy cytomegalovirus mononucleosis is a distinct clinicopathologic syndrome. Am J Med Sci. 2010;339(4):395–399.
- Iheozor-Ejiofor R, Vapalahti K, Sironen T, et al. Neutralizing antibody titers in hospitalized patients with acute puumala orthohantavirus infection do not associate with disease severity. Viruses. 2022;14(5):901.
- Taylor SL, Wahl-Jensen V, Copeland AM, et al. Endothelial cell permeability during Hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system. PLoS Pathog. 2013;9(7):e1003470.